Marlborough, MA, 5 January 2012 - Optos plc (LSE: OPTS), a leading provider of devices and solutions to eye care professionals for improved patient care, announced a visit to its manufacturing facility in Southborough, Massachusetts by Lt. Governor Timothy Murray. During his visit, Lt. Governor Murray highlighted the Patrick-Murray Administration’s recently launched Massachusetts Advanced Manufacturing Collaborative, which outlines a new roadmap for manufacturing job growth. The objective is to build a state-level alliance with industry, academia and government that can deliver a new generation of advanced manufacturing jobs.
Tom Motta, Chief Operating Officer, led Lt. Governor Murray on the tour to demonstrate how Optos utilized a Work Force Training grant to educate employees on the concepts of Lean business processes and procedures. According to Motta, “Optos embarked on the Lean journey 24 months ago to improve our manufacturing capabilities and support Optos’ goal to be a leading medical device provider in Massachusetts. Our on-going objective is to create a work environment where each of our associates is given the opportunity, time, and Lean training to improve processes and ultimately the support to our customers. We call it “Every One Every Day”. The tour included examples of operational excellence resulting in large savings in manufacturing time and a look at Optos’ new $500k 5,000 sq ft medical grade warehouse and clean environment manufacturing facility for the devices that capture optomap images.
The Lt Governor commented at the end of the tour, “Optos is an example of a modern manufacturing facility with a focus on process and results. This focus is part of the cornerstone of the Massachusetts Advanced Manufacturing Collaborative, and I look forward to seeing more great work achieved by Optos right here in Massachusetts.”
Leslie Amodei, Director Global Marketing
About Optos Plc
Optos plc is Building The retina company. Our vision is to be recognized as a leading provider of devices and solutions to ophthalmic professionals for improved patient care. Optos' core devices produce ultra-widefield, high resolution digital images of approximately 82% of the retina, something no other device is capable of doing in any one non contact image capture. The images provide optometrists and ophthalmologists with enhanced clinical information which facilitates the early detection, management and treatment of disorders and diseases evidenced in the retina such as retinal detachments and tears, glaucoma, diabetic retinopathy and age-related macular degeneration. Retinal imaging can also indicate evidence of non-eye or systemic diseases such as hypertension and certain cancers. Optos believes that its technology provides an unequalled combination of widefield retinal imaging, speed and convenience for both the practitioner and patient.
Optos continues to broaden its product range and support its customers by way of acquisitions and expansion of its distribution network to support future growth into new and existing geographies.
Approximately 4,000 devices have been installed worldwide with the majority in North America, with an increasing presence in the EU and other overseas markets. In October 2011, the 30 million optomap patient was imaged underscoring the value of data provided with optomap.
For more information about Optos and optomap ultra-widefield retinal imaging please visit our website www.optos.com